<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tirbanibulin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tirbanibulin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tirbanibulin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="130381" href="/d/html/130381.html" rel="external">see "Tirbanibulin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55413819"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Klisyri</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F55205296"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antimicrotubular;</li>
<li>
                        Topical Skin Product</li></ul></div>
<div class="block doa drugH1Div" id="F55424725"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4bb58f89-580c-47cf-bf9c-e5c96334fe50">Actinic keratosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Actinic keratosis: Topical:</b> Apply once daily to evenly cover up to a 25 cm<sup>2</sup> area (using no more than 1 single-dose packet per application) for 5 consecutive days.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F55424727"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F55424728"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F55424726"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F55832561"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Dermatologic reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Local skin reactions (LSR), including <b>crusted skin</b>, <b>dermal ulcer</b>, <b>skin erosion</b>, <b>erythema of skin</b>, <b>exfoliation of skin/scaling</b>, <b>pustules</b>, <b>skin vesicle</b>, and <b>swelling of skin</b> may commonly occur. Most LSRs are mild and transient; however, severe LSRs have also been reported. Most LSRs spontaneously resolved/stabilized within 2 to 4 weeks during clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33196758']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33196758'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; LSRs appear 2 to 4 days after initiation of therapy and peak by the end of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33196758']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33196758'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Occlusion following application</p>
<p style="text-indent:-2em;margin-left:6em;">• Application to skin that has not fully healed from prior drug, procedure, or surgical treatment.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55209978"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Dermatologic: Crusted skin (mild to moderate: 14% to 30%; severe: 2%)<span class="lexi-table-link-container"> (<a aria-label="Crusted Skin table link" class="lexi-table-link" data-table-id="lexi-content-crusted-skin" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-crusted-skin')">table 1</a>)</span><span class="table-link" style="display:none;">Crusted Skin</span>, erythema of skin (63%; mild erythema of skin: 22%; severe erythema: 6%)<span class="lexi-table-link-container"> (<a aria-label="Erythema of Skin table link" class="lexi-table-link" data-table-id="lexi-content-erythema-of-skin" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-erythema-of-skin')">table 2</a>)</span><span class="table-link" style="display:none;">Erythema of Skin</span>, exfoliation of skin (mild to moderate: 26% to 47%; severe: 9%)<span class="lexi-table-link-container"> (<a aria-label="Exfoliation of Skin table link" class="lexi-table-link" data-table-id="lexi-content-exfoliation-of-skin" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-exfoliation-of-skin')">table 3</a>)</span><span class="table-link" style="display:none;">Exfoliation of Skin</span>, swelling of skin (mild to moderate: 9% to 29%; severe &lt;1%)<span class="lexi-table-link-container"> (<a aria-label="Swelling of Skin table link" class="lexi-table-link" data-table-id="lexi-content-swelling-of-skin" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-swelling-of-skin')">table 4</a>)</span><span class="table-link" style="display:none;">Swelling of Skin</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Crusted Skin" frame="border" id="lexi-content-crusted-skin" rules="all">
<caption style="text-align:center;">
<b>Tirbanibulin: Adverse Reaction: Crusted Skin</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo (Vehicle)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vehicle)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mild: 30%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Moderate: 14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe: 2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Erythema of Skin" frame="border" id="lexi-content-erythema-of-skin" rules="all">
<caption style="text-align:center;">
<b>Tirbanibulin: Adverse Reaction: Erythema of Skin</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo (Vehicle)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vehicle)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mild: 22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Moderate: 63%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe: 6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Exfoliation of Skin" frame="border" id="lexi-content-exfoliation-of-skin" rules="all">
<caption style="text-align:center;">
<b>Tirbanibulin: Adverse Reaction: Exfoliation of Skin</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo (Vehicle)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vehicle)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mild: 26%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Moderate: 47%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe: 9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Swelling of Skin" frame="border" id="lexi-content-swelling-of-skin" rules="all">
<caption style="text-align:center;">
<b>Tirbanibulin: Adverse Reaction: Swelling of Skin</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo (Vehicle)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vehicle)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mild: 29%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Moderate: 9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe: 0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermal ulcer (mild to moderate: ≤9%)<span class="lexi-table-link-container"> (<a aria-label="Dermal Ulcer table link" class="lexi-table-link" data-table-id="lexi-content-dermal-ulcer" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dermal-ulcer')">table 5</a>)</span><span class="table-link" style="display:none;">Dermal Ulcer</span>, pustules (mild to moderate: ≤7%, severe: &lt;1%)<span class="lexi-table-link-container"> (<a aria-label="Pustules table link" class="lexi-table-link" data-table-id="lexi-content-pustules" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pustules')">table 6</a>)</span><span class="table-link" style="display:none;">Pustules</span>, skin erosion (mild to moderate: ≤9%)<span class="lexi-table-link-container"> (<a aria-label="Skin Erosion table link" class="lexi-table-link" data-table-id="lexi-content-skin-erosion" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-skin-erosion')">table 7</a>)</span><span class="table-link" style="display:none;">Skin Erosion</span>, skin vesicle (mild to moderate: ≤7%, severe: &lt;1%)<span class="lexi-table-link-container"> (<a aria-label="Skin Vesicle table link" class="lexi-table-link" data-table-id="lexi-content-skin-vesicle" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-skin-vesicle')">table 8</a>)</span><span class="table-link" style="display:none;">Skin Vesicle</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dermal Ulcer" frame="border" id="lexi-content-dermal-ulcer" rules="all">
<caption style="text-align:center;">
<b>Tirbanibulin: Adverse Reaction: Dermal Ulcer</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo (Vehicle)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vehicle)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mild: 9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Described as "Erosion/Ulceration"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Moderate: 3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Described as "Erosion/Ulceration"</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pustules" frame="border" id="lexi-content-pustules" rules="all">
<caption style="text-align:center;">
<b>Tirbanibulin: Adverse Reaction: Pustules</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo (Vehicle)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vehicle)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mild: 7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Described as "Vesiculation/Pustulation"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Moderate: 0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Described as "Vesiculation/Pustulation"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe: 0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Described as "Vesiculation/Pustulation"</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Skin Erosion" frame="border" id="lexi-content-skin-erosion" rules="all">
<caption style="text-align:center;">
<b>Tirbanibulin: Adverse Reaction: Skin Erosion</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo (Vehicle)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vehicle)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mild: 9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Described as "Erosion/Ulceration"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Moderate: 3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Described as "Erosion/Ulceration"</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Skin Vesicle" frame="border" id="lexi-content-skin-vesicle" rules="all">
<caption style="text-align:center;">
<b>Tirbanibulin: Adverse Reaction: Skin Vesicle</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo (Vehicle)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tirbanibulin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vehicle)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mild: 7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Described as "Vesiculation/Pustulation"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Moderate: 0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Described as "Vesiculation/Pustulation"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe: 0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">353</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Described as "Vesiculation/Pustulation"</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site pain (10%), application-site pruritus (9%)</p></div>
<div class="block coi drugH1Div" id="F55205115"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F55424716"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: May cause eye irritation; avoid contact with eyes or periocular area during and after application.</p></div>
<div class="block foc drugH1Div" id="F55413820"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Klisyri: 1% (5 ea) [contains propylene glycol]</p></div>
<div class="block geq drugH1Div" id="F55413818"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55430193"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Klisyri External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per each): $266.73</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F55424729"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Topical:</b> Apply to keratotic lesions only; do not cover with an occlusive dressing. Wash hands immediately after application. Avoid washing or touching the treatment area for ~8 hours; may wash area with a mild soap and water after this time. Avoid application near or around the mouth, lips, or eyes. If accidental contact with eyes occurs, flush with water and contact health care provider.</p></div>
<div class="block use drugH1Div" id="F55205114"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Actinic keratosis:</b> Topical treatment of actinic keratosis on the face or scalp.</p></div>
<div class="block mst drugH1Div" id="F55424711"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Tirbanibulin may be confused with eribulin, terbanifine, terbutaline.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">This medication is in a class the Institute for Safe Medication Practices includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F55217828"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F55217825"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F55424714"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in some animal reproduction studies following oral administration of tirbanibulin in doses providing greater systemic exposure than a maximum recommended human dose.</p></div>
<div class="block brc drugH1Div" id="F55424715"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if tirbanibulin is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F55424731"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for local skin reactions and ophthalmic adverse reactions.</p></div>
<div class="block pha drugH1Div" id="F55424719"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Tirbanibulin is a microtubule inhibitor; it inhibits tubulin polymerization and disrupts Src kinase signaling, which are upregulated in actinic keratosis (Kempers 2020).</p></div>
<div class="block phk drugH1Div" id="F55424721"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 88%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 and CYP2C8 (minor) to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Median: ~7 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522292"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Klisyri</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Klisyri</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Klisyri</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Klisyri</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Klisyri</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Klisyri</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Klisyri</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Klisyri</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Klisyri</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33196758">
<a name="33196758"></a>Kempers S, DuBois J, Forman S, et al. Tirbanibulin ointment 1% as a novel treatment for actinic keratosis: phase 1 and 2 results. <i>J Drugs Dermatol</i>. 2020;19(11):1093-1100. doi:10.36849/JDD.2020.5576<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tirbanibulin-drug-information/abstract-text/33196758/pubmed" id="33196758" target="_blank">33196758</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Klisyri (tirbanibulin) [prescribing information]. Malvern, PA: Almirall LLC; August 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 130360 Version 40.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
